Back to Search
Start Over
Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase
- Source :
- The journal of allergy and clinical immunology. In practice. 9(3)
- Publication Year :
- 2020
- Subjects :
- severe asthma
medicine.medical_specialty
Antibodies, Monoclonal, Humanized
Eosinophils
Humans
Anti-Asthmatic Agents
Churg-Strauss Syndrome
Churg-strauss syndrome
Gastroenterology
Anti-asthmatic Agent
Antibodies
Internal medicine
Monoclonal
Remission phase
medicine
Immunology and Allergy
Asthmatic patient
Humanized
Mepolizumab
Mepolizumab, severe asthma, EGPA
business.industry
Mepolizumab 100 MG
medicine.disease
EGPA
business
Subjects
Details
- ISSN :
- 22132201
- Volume :
- 9
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- The journal of allergy and clinical immunology. In practice
- Accession number :
- edsair.doi.dedup.....ac14effa025f87353dd719d45c79d82d